Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional, molecular, and digital measurements of biological age.

The Journal of clinical investigation·2026
Same author

A tribute to Eugene Braunwald (1929-2026).

The Journal of clinical investigation·2026
Same author

Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis.

Blood·2026
Same author

Metabolic Vulnerability Index and Risk of Total Mortality: Findings From the Multi-Ethnic Study of Atherosclerosis.

Circulation. Population health and outcomes·2026
Same author

Plasminogen activator inhibitor 1 promotes aortic aging-like pathophysiology in humans and mice.

The Journal of clinical investigation·2025
Same author

Mouse model hints at pharmacogenomic strategies for stroke treatment in patients possessing a risk variant.

The Journal of clinical investigation·2023

Related Experiment Video

Updated: Jul 11, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

PAI-1 antagonists: predictable indications and unconventional applications.

Douglas E Vaughan1, Bart M De Taeye, Mesut Eren

  • 1Division of Cardiovascular Medicine,Vanderbilt University Medical Center, Nashville, TN 37232, USA. doug.vaughan@vanderbilt.edu

Current Drug Targets
|September 28, 2007
PubMed
Summary

Directly increasing fibrinolysis is limited to short-term use. New PAI-1 antagonists offer potential long-term therapeutic options for thrombotic disorders and other diseases by modulating the fibrinolytic system.

Related Experiment Videos

Last Updated: Jul 11, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicine

Background:

  • Current thrombolytic agents effectively treat acute thrombotic events but are unsuitable for long-term use.
  • Indirect methods to enhance fibrinolysis involve reducing plasminogen activator inhibitor-1 (PAI-1) levels using drugs like ACE inhibitors and hormone therapy.
  • Research is actively pursuing the development of synthetic, selective PAI-1 antagonists.

Purpose of the Study:

  • To explore the potential of PAI-1 antagonists as a therapeutic strategy.
  • To identify potential applications for PAI-1 antagonists in various diseases.
  • To advance the understanding of the fibrinolytic system's role in human pathology.

Main Methods:

  • Review of existing literature on thrombolytic agents and PAI-1 inhibitors.
  • Analysis of the pharmacological mechanisms of PAI-1 modulation.
  • Identification of diseases where PAI-1 plays a significant role.

Main Results:

  • PAI-1 antagonists represent a novel approach to augmenting fibrinolytic activity.
  • Potential therapeutic applications include arterial and venous thrombotic disorders, amyloidosis, obesity, polycystic ovarian syndrome, and type 2 diabetes mellitus.
  • Selective PAI-1 antagonists offer a promising avenue for long-term therapeutic intervention.

Conclusions:

  • PAI-1 antagonists have the potential to overcome the limitations of current thrombolytic therapies.
  • Targeting PAI-1 could offer new treatment strategies for a range of complex diseases.
  • Further research and development of PAI-1 antagonists are warranted to fully realize their therapeutic potential.